Subscription nearly 40 million yuan! Sansheng pharmaceutical invests in gensight to enter the field of gene therapy

Recently, gensight biologics announced that it obtained up to 12 million euros of committed financing from kreos capital VI (UK) Limited in the form of bond financing, and issued the first part of 6 million euros of withdrawal notice Meanwhile, Sansheng pharmaceutical and sofinnova crossover I SLP (one of the major shareholders of gensight) subscribed 5 million euros and 4 million euros respectively For Sansheng pharmaceutical's subscription of new shares, gensight has agreed to grant Sansheng pharmaceutical the priority of licensing, joint development and production of its two leading products in Greater China, including gs010 for the treatment of Leber hereditary optic neuropathy (LHON) and gs030 for the treatment of retinitis pigmentosa (gensight will Buy back the priority at the agreed price) Upon completion of this financing, gensight and Sansheng pharmaceutical immediately began discussions on the potential licensing or joint development cooperation of the two leading products in Greater China In response, Dr Lou Jing, chairman and CEO of Sansheng pharmaceutical, said: "the investment in gensight is in line with our goal of exploring potential therapeutic strategies Gene therapy technology owned by gensight has great potential to solve the current unmet medical needs As one of the leading Biopharmaceutical Enterprises in China, Sansheng pharmaceutical is looking forward to cooperating with gensight and entering the field of gene therapy " Gensight is a French biotech company focused on the discovery and development of innovative gene therapies for the treatment of retinal degeneration and central nervous system disorders Currently, gs010, its leading candidate, is undergoing phase III trials for the treatment of hereditary optic neuropathy (LHON) Sansheng pharmaceutical was founded in 1993, which can be said to be an old biopharmaceutical enterprise In 2007, Sansheng pharmaceutical was listed on NASDAQ In 2013, the buyer group led by the management and CITIC Industrial Fund completed privatization and delisted from NASDAQ In 2015, it was listed on the Hong Kong Stock Exchange and included in the Hang Seng Composite large and medium-sized stock index At present, the main listed products of Sansheng pharmaceutical are tebio and yisepu The former is the first and only commercial recombinant human thrombopoietin product in the world, and the latter is the first TNF - α inhibitor in China According to Sansheng pharmaceutical's report for the first half of 2019, in the first half of this year, the sales volume of special Australia was 1.194 billion yuan, and the sales volume of yisaipu was 501 million yuan The revenue of these two drugs accounted for 63.9% of the total revenue However, affected by Sumeria's inclusion in the national health insurance catalogue in 2019, it is expected that the sales of yisaipu will decline in the future Sumil is a direct competitor of GSP in the market of ankylosing spondylitis and rheumatoid arthritis Sansheng pharmaceutical's product R & D pipeline layout has been improved At present, it has 32 products under development, 22 of which are national first-class new drugs Among these products under research, the products in the field of tumor occupy nearly 1 / 3 Figure 1: Sansheng pharmaceutical product pipeline Source: Sansheng pharmaceutical performance briefing, Zhongkang Industrial Capital Research Center In fact, Sansheng pharmaceutical has been actively arranging the next generation tumor immune projects such as double antibody, cell therapy and macrophage targeted immunotherapy through independent research and development and foreign cooperation, so as to continuously increase its long-term competitiveness In terms of independent research and development, the company has a number of bispecific antibody projects in pre clinical development, including PD-1 BsAb, HER2 BsAb, EGFR BsAb, etc In terms of foreign cooperation, the company has at least five cooperation events this year Except that today's cooperation does not involve tumor products, other cooperation includes tumor products It can be seen that it attaches great importance to the field of tumor.